Biopeak secures investment of $2.7 M from Nikhil Kamath to scale longevity care

image credit- freepik

Biopeak, India’s first longevity and health optimisation brand, has raised 2.7 million in its latest funding round led by repeat investor Nikhil Kamath, through NKSquared, the investment arm of Zerodha. 

The follow-on investment reflects continued conviction in Biopeak’s work to build structured, preventive care systems for longevity in India. While India has made significant progress in acute and episodic care, organised clinical models focused on early detection, longitudinal tracking, and healthspan remain limited.

Biopeak is addressing this gap by building multidisciplinary specialist-led programs that combine diagnostics, proprietary AI-driven insights, targeted clinical interventions, and sustained follow-up over time. Its approach is designed around Indian health profiles and disease patterns, enabling early risk identification, health optimisation, and supported recovery and regeneration. 

The capital will be used to expand Biopeak’s presence and deepen capabilities across diagnostics, proprietary AI, research, and program development. This includes the launch of a new flagship centre in Bengaluru, continued investment in clinical longevity programs, and team expansion across clinical, research, product, and operations. Building on growing consumer acceptance, Biopeak is strengthening its network of global advisors and institutional partners to advance protocol development and clinical governance.